General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Forest Laboratories Canada
Indication:
Irritable bowel syndrome with constipation
Last updated November 2, 2015
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Non-Small Cell Lung Cancer (First Line)
Last updated October 8, 2015
Fibristal (ulipristal acetate)
Status:
Concluded with an LOI
Manufacturer:
Allergan Inc.
Indication:
Uterine fibroids (signs and symptoms)
Last updated September 18, 2015
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Peripheral T-cell Lymphoma (PTCL)
Last updated September 16, 2015
Aptiom (eslicarbazepine acetate)
Status:
Concluded with an LOI
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated September 8, 2015
Status:
Negotiations were not pursued
Manufacturer:
Bayer Inc.
Indication:
Metastatic Colorectal Cancer
Last updated August 31, 2015
Status:
Concluded with an LOI
Manufacturer:
Shire Pharma Canada ULC
Indication:
Hereditary Angioedema
Last updated August 28, 2015
Simbrinza (brinzolamide/brimonidine)
Status:
Concluded with an LOI
Manufacturer:
Alcon Canada Inc.
Indication:
Glaucoma and Ocular Hypertension
Last updated August 27, 2015
Perjeta/Herceptin (pertuzumab/trastuzumab)
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neoadjuvant Breast Cancer
Last updated July 29, 2015
Status:
Negotiations were not pursued
Manufacturer:
Bayer Inc.
Indication:
Metastatic Progressive Differentiated Thyroid Carcinoma
Last updated July 29, 2015